Global Chronic Liver Disease Therapeutics Market to Surpass US$ 24.9 Billion by 2027, Says Coherent Market Insights

SEATTLE–(BUSINESS WIRE)–#ChronicLiverDiseases–According to Coherent Market Insights, the global chronic liver diseases therapeutics market is estimated to be valued at US$ 12.8 billion in 2020 and is expected to exhibit a CAGR of 9.7% during the forecast period (2020-2027).

Key Trends and Analysis:

Approval and launch of novel therapies for treatment of liver diseases is expected to drive growth of the global chronic liver disease therapeutics market. For instance, in March 2020, the U.S. Food and Drug Administration (FDA) approved a combination of the checkpoint inhibitors, Opdivo (nivolumab) and Yervoy (ipilimumab), for advanced hepatocellular carcinoma, a liver cancer.

Furthermore, the increasing prevalence of liver cancer is expected to propel growth of the global chronic liver diseases therapeutics market during the forecast period. For instance, according to The American Cancer Society, in 2020, the U.S. is expected to witness around 42,810 new cases of primary liver cancer and around 30,160 deaths due to primary liver cancer and intrahepatic bile duct cancer.

The global chronic liver diseases therapeutics market is expected to witness significant growth owing to increasing research for identifying the causes of liver cancer. For instance, in 2019, the U.S FDA accepted the NDA (new drug application) filed by Intercept Pharmaceuticals, Inc., this NDA filed drug is developed for the treatment of liver fibrosis due to nonalcoholic steatohepatitis.

(Read more…)

Request for Sample copy @ https://www.coherentmarketinsights.com/insight/request-sample/4047

Key Market Takeaways:

The global chronic liver diseases therapeutics market is expected to exhibit a CAGR of 9.7% during the forecast period (2020-2027) owing to R&D of novel therapies. For instance, in April 2020, researchers from the Osaka City University Graduate School of Medicine, Japan, in the Journal of Hepatology, reported novel highlights in the pathophysiology of human nonalcoholic steatohepatitis with fibrosis and suggested a new approach for the treatment of the condition using cytoglobin inducer.

Key players in the North America chronic liver diseases therapeutics market are focused on launching new products in this market. For instance, in March 2020, the U.S. Food and Drug Administration (FDA) approved a combination of checkpoint inhibitors, Opdivo (nivolumab) and Yervoy (ipilimumab), for advanced hepatocellular carcinoma, a liver cancer.

Companies Profiled in this Research Report—

Astellas Pharma Inc., Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4047

Market Segmentation:

• Global Chronic Liver Diseases Therapeutics Market, By Therapy Type:
  • Anti-Rejection Drugs/Immunosuppressants
  • Chemotherapy Drugs
  • Targeted therapy
  • Vaccines
  • Anti-Viral Drugs
  • Immunoglobulins
  • Corticosteroids
• Global Chronic Liver Diseases Therapeutics Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Chronic Liver Diseases Therapeutics Market, By Region:
  • North America
    • By Country:
      • U.S.
      • Canada
  • Europe
    • By Country:
      • U.K.
      • Germany
      • Italy
      • Spain
      • France
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country:
      • Australia
      • India
      • China
      • Japan
      • ASEAN
      • South Korea
      • Rest of Asia Pacific
  • Latin America
    • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Middle East
    • By Country:
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa

Related Market Intelligence Report:

Hypertriglyceridemia Therapeutics Market, by Type (Primary and Secondary), by Drug Class (Statins, Fibrates, Niacin, Omega-3 Fatty Acids, and HMG-CoA Reductase inhibitors), by Distribution Channel (Online Pharmacy, Retail Pharmacy, Hospital Pharmacy, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027

Read more: https://www.coherentmarketinsights.com/market-insight/hypertriglyceridemia-therapeutics-market-4020

Allergic Asthma Therapeutics Market, by Drug Type (Corticosteroids, Bronchodilators, Leukotriene modifiers, Immunotherapy, Biologics, and Others), by Route of Administration (Oral, Inhaled, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027

Read more: https://www.coherentmarketinsights.com/market-insight/allergic-asthma-therapeutics-market-4019

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.

Contacts

Mr. Shah

Senior Client Partner – Business Development

Coherent Market Insights

Phone:
US: +1-206-701-6702

UK: +44-020-8133-4027

Japan: +81-050-5539-1737

India: +91-848-285-0837

Email: [email protected]
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter